Suchergebnisse - "Huang, Xin"

PubPharm (14)

1

Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer

enthalten in: Future oncology (London, England) | 2024

von Robert, N. | Chen, C. | Kim, S. | +7

2

The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer : a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results

enthalten in: Future oncology (London, England) | 2024

von Rugo, H. | Im, S. | Joy, A. | +11

3

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Pfeiler, G. | Hlauschek, D. | Mayer, E. | +49

4

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer : Post hoc analyses from PALOMA-2 and PALOMA-3

enthalten in: Breast (Edinburgh, Scotland) | 2022

von Rugo, H. | Im, S. | Joy, A. | +11

5

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC : Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Cristofanilli, M. | Rugo, H. | Im, S. | +17

6

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Martín, M. | Zielinski, C. | Ruiz-Borrego, M. | +23

CommentIn: Eur J Cancer. 2022 Aug;171:43. - PMID 35704973

7

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18)

enthalten in: Breast cancer research and treatment | 2020

von Finn, R. | Boer, K. | Bondarenko, I. | +13

8

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

enthalten in: The breast journal | 2020

von Gelmon, K. | Cristofanilli, M. | Rugo, H. | +11

9

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : PALOMA-3 subgroup analysis of Japanese patients

enthalten in: International journal of clinical oncology | 2019

von Masuda, N. | Inoue, K. | Nakamura, R. | +11

10

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

enthalten in: The New England journal of medicine | 2018

von Turner, N. | Slamon, D. | Ro, J. | +16

CommentIn: Nat Rev Clin Oncol. 2018 Dec;15(12):725. - PMID 30397331